Template:Second-generation BTKi table: Difference between revisions

From Embryology
(Created page with "{| |+ Novel BTK inhibitors in development for treatment of CLL |- ! BTK inhibitor ! BTK binding mechanism ! Selectivity for BTK ! Relevant non-BTK targets ! Phase of clinical...")
 
mNo edit summary
 
(19 intermediate revisions by the same user not shown)
Line 1: Line 1:
{|
{|
|+ Novel BTK inhibitors in development for treatment of CLL
|+ '''Second-generation Bruton’s Tyrosine Kinase Inhibitors (BTKi) for CCL Treatment'''
|-bgcolor="CEDFF2"
! width=110px|BTK inhibitor
! width=150px|BTK binding mechanism
! width=80px|Selectivity for BTK
! width=320px|Relevant non-BTK targets
! width=90px|Clinical Phase
|-
|-
! BTK inhibitor
| Acalabrutinib
! BTK binding mechanism
| Covalent, irreversible
! Selectivity for BTK
| High
! Relevant non-BTK targets
| N/A
! Phase of clinical development
| II/III
|-bgcolor="F5FAFF"
| Zanubrutinib
| Covalent, irreversible
| Moderate
| N/A
| II/III
|-
|-
Acalabrutinib Zanubrutinib Tirabrutinib Vecabrutinib LOXO-305 ARQ-531
| Tirabrutinib
BTK Bruton’s tyrosine
| Covalent, irreversible
mitogen-activated protein kinase kinase 1
| High
 
| N/A
 
| I/II
Covalent, irreversible Covalent, irreversible Covalent, irreversible Non-covalent, reversible Non-covalent, reversible Non-covalent, reversible
|-bgcolor="F5FAFF"
 
| Vecabrutinib
 
| Non-covalent, reversible
High Moderate High Moderate High Low
| Moderate
 
| interleukin-2-inducible (ITK)
N/A
| I/II
N/A
|-
N/A
| LOXO-305
ITK
| Non-covalent, reversible
N/A
| High  
LYN, MEK1
| N/A
 
| I
II/III II/III I/II I/II
|-bgcolor="F5FAFF"
I I
| ARQ-531
| Non-covalent, reversible
| Low 
| Lck/Yes novel tyrosine kinase (LYN),<br>mitogen-activated protein kinase kinase 1 (MEK1)
| I
|-
|-
| colspan=5|Table data {{#pmid:31028669|PMID31028669}}
| colspan=5|Table data {{#pmid:31028669|PMID31028669}}
|}
|}

Latest revision as of 15:11, 30 April 2019

Second-generation Bruton’s Tyrosine Kinase Inhibitors (BTKi) for CCL Treatment
BTK inhibitor BTK binding mechanism Selectivity for BTK Relevant non-BTK targets Clinical Phase
Acalabrutinib Covalent, irreversible High N/A II/III
Zanubrutinib Covalent, irreversible Moderate N/A II/III
Tirabrutinib Covalent, irreversible High N/A I/II
Vecabrutinib Non-covalent, reversible Moderate interleukin-2-inducible (ITK) I/II
LOXO-305 Non-covalent, reversible High N/A I
ARQ-531 Non-covalent, reversible Low Lck/Yes novel tyrosine kinase (LYN),
mitogen-activated protein kinase kinase 1 (MEK1)
I
Table data [1]
  1. ↑ Bond DA & Woyach JA. (2019). Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep , , . PMID: 31028669 DOI.